Response Assessment to Immuno- & Targeted Therapies
Sunrise Course
ORGANIZERS: Nandita DeSouza, Sonal Krishan
Thursday, 09 May 2024
Nicoll 3
07:00 -
08:00
Moderators: Fernando Arias-Mendoza & Mary McLean
Skill Level: Intermediate to Advanced
Session Number: S-Th-04
CME Credit
Session Number: S-Th-04
Overview
This course presents response assessment measures both qualitative and quantitative applicable to targetted and immunotherapies. In particular, the use of criteria that are beyond standard unidimensional measurements (RECIST criteria) will be discussed.
Target Audience
Clinicians with an interest in treatment response assessment and the use of targetted therapies particularly within clinical trials. Scientists involved in clinical trials.
Educational Objectives
As a result of attending this course, participants should be able to:
- Describe the challenges of response assessment to targeted and immunotherapies;
- Review current and potential quantitative methods of response assessment to targeted and immunotherapies; and
- Describe the potential and increasing role of MR Elastography in assessing response to targeted and immunotherapies.
| 07:00 | | Monitoring Response to Targeted & Immunotherapy: iRECIST, DWI & More Natalie Serkova Keywords: Education Committee: Clinical MRI The primary focus of this talk is to discuss the evaluation criteria, advanced imaging protocols and new imaging biomarkers to assess treatment response in cancer patients treated with novel targeted and immune-therapies. For decades, one-dimensional measurements of a targeted tumor lesion (mostly based on sequential CT and sometimes MRI, depending on the site of malignancies) have been used as Response Evaluation Criteria in Solid Tumors (RECIST) to cytotoxic chemotherapeutics. Clinical needs for advanced MRI protocols (DWI, DCE-MRI, complementary PET) for early response to cytostatic signal transduction inhibitors and RECIST modification for checkpoint inhibitors (iRECIST) will be discussed. |
| 07:30 | | Translation of Quantitative MRI Biomarkers for Assessing Treatment Response: Lessons Learned with MR Elastography Richard Ehman Keywords: Contrast mechanisms: Elastography, Image acquisition: Quantification, Cross-organ: Tissue characterisation A common task in diagnostic imaging is to assess the response of disease to therapy. MRI is inherently quantitative, providing access to many powerful biomarkers for characterizing tissue. Yet, few quantitative imaging techniques have been widely adopted in clinical practice, other than simply obtaining and recording measurements of the spatial dimensions of focal lesions (such as RECIST criteria). This presentation will review emerging evidence for several applications of MR elastography as a quantitative biomarker in cancer management. Lessons learned in gaining clinical adoption of MRE as an accepted surrogate for treatment response in chronic liver disease will be described. |